ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass

@inproceedings{Barreto2017ACVR2BFcCC,
  title={ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass},
  author={Rafael Ferreira Barreto and Yukiko Kitase and Tsutomu Matsumoto and Fabrizio Pin and Kyra C. Colston and Katherine E. Couch and Thomas M. O’Connell and Marion E. Couch and Lynda F Bonewald and Andrea Bonetto},
  booktitle={Scientific Reports},
  year={2017}
}
Chemotherapy promotes the development of cachexia, a debilitating condition characterized by muscle and fat loss. ACVR2B/Fc, an inhibitor of the Activin Receptor 2B signaling, has been shown to preserve muscle mass and prolong survival in tumor hosts, and to increase bone mass in models of osteogenesis imperfecta and muscular dystrophy. We compared the effects of ACVR2B/Fc on muscle and bone mass in mice exposed to Folfiri. In addition to impairing muscle mass and function, Folfiri had severe… CONTINUE READING
BETA
3
Twitter Mentions

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 126 REFERENCES

GDF8 inhibits bone formation and promotes bone resorption in mice.

  • Clinical and experimental pharmacology & physiology
  • 2017

Similar Papers

Loading similar papers…